Kunxue Hong

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Corrigendum to 'optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China'[journal of virological methods 185 (2012) 267- 275].

Corrigendum to 'optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China'[journal of virological methods 185 (2012) 267- 275].

Journal: Journal of virological methods
Published: December 09, 2025

Multiple Mechanisms of HIV-1 Resistance to PGT135 in a Chinese Subtype B' Slow Progressor.

Multiple Mechanisms of HIV-1 Resistance to PGT135 in a Chinese Subtype B' Slow Progressor.

Journal: Pathogens (Basel, Switzerland)
Published: April 16, 2025

Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Journal: Infectious diseases and therapy
Published: June 14, 2024

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Journal: Infectious diseases and therapy
Published: August 19, 2023

Impact of pretreatment low-abundance HIV-1 drug resistance on virological failure after 1 year of antiretroviral therapy in China.

Impact of pretreatment low-abundance HIV-1 drug resistance on virological failure after 1 year of antiretroviral therapy in China.

Journal: The Journal of antimicrobial chemotherapy
Published: May 17, 2023

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.

Journal: Frontiers in immunology
Published: April 04, 2023

Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.

Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.

Journal: Pathogens (Basel, Switzerland)
Published: April 01, 2023

Characterization of a VRC01-like antibody lineage with immature VL from an HIV-1 infected Chinese donor.

Characterization of a VRC01-like antibody lineage with immature VL from an HIV-1 infected Chinese donor.

Journal: Molecular immunology
Published: July 24, 2022

Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.

Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.

Journal: Frontiers in cellular and infection microbiology
Published: January 26, 2022

Impact of HIV Pretreatment Drug Resistance on Virological Failure After One-Year Antiretroviral Therapy - China, 2018-2019.

Impact of HIV Pretreatment Drug Resistance on Virological Failure After One-Year Antiretroviral Therapy - China, 2018-2019.

Journal: China CDC weekly
Published: November 20, 2021

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity.

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity.

Journal: Vaccines
Published: February 16, 2021

Characterization of antibody-dependent cellular cytotoxicity induced by the plasma from persons living with HIV-1 based on target cells with or without CD4 molecules.

Characterization of antibody-dependent cellular cytotoxicity induced by the plasma from persons living with HIV-1 based on target cells with or without CD4 molecules.

Journal: Microbes and infection
Published: January 29, 2021
Showing 1-12 of 36

Last Updated: 09/26/2026